BioCentury
ARTICLE | Company News

D-Pharm, Thrombotech deal

March 5, 2012 8:00 AM UTC

D-Pharm said it is in negotiations to acquire stroke company Thrombotech in a stock deal after discontinuing development of its own stroke therapy in January due to lack of efficacy. On Jan. 24, D-Pharm plummeted NIS11.10 (85%) to NIS2 after a DSMB recommended stopping the Phase III MACSI trial of DP-b99 to treat acute ischemic stroke; an interim analysis showed the trial met criteria for futility. DP-b99 is a membrane-activated lipophilic chelator of zinc, copper and calcium ions. D-Pharm's next most advanced product is DP-VPA, a phospholipid derivative of valproic acid formulated with D-Pharm's Regulated Activation of Prodrugs (D-RAP) technology. The product has completed a Phase II trial in patients with complex partial epilepsy. ...